Travere Therapeutics, Inc. (TVTX)
$65.49-$2.03 (-3.01%) Today
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 7 | 24,500 | $1.36M |
| Option exercise | 8 | 49,000 | |
| Bona-fide gift | 1 | 468 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
69 Form 4 filings on record, the earliest from Oct 4, 2024, newest first. Filing history page 3 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
 Elizabeth E. Reed - Officer | Option exercise | Common Stock | 10,000 | $19.08 | $191K | |
| Elizabeth E. Reed - Officer | Open-market sale | Common Stock | 10,000 | $25.00 | $250K | |
| Elizabeth E. Reed - Officer | Option exercise | Employee stock option (right to buy) | 10,000 | $0.00 | - | |
| Christopher R. Cline - Officer | Open-market sale | Common Stock | 454 | $18.20 | $8K | |
| Christopher R. Cline - Officer | Open-market sale | Common Stock | 119 | $19.71 | $2K | |
| Christopher R. Cline - Officer | Open-market sale | Common Stock | 470 | $17.31 | $8K | |
 Jula Inrig - Officer | Open-market sale | Common Stock | 815 | $14.65 | $12K | |
| Gary A. Lyons | Grant or award | Common Stock | 6,500 | $0.00 | - | |
| Gary A. Lyons | Grant or award | Stock option (right to buy) | 19,500 | $0.00 | - | |
| Elizabeth E. Reed - Officer | Option exercise | Common Stock | 4,920 | - | - | |
| Elizabeth E. Reed - Officer | Open-market sale | Common Stock | 4,920 | $21.05 | $104K | |
| Elizabeth E. Reed - Officer | Option exercise | Performance-based restricted stock units | 4,920 | $0.00 | - | |
| Sandra Calvin - Officer | Option exercise | Common Stock | 15,000 | $12.67 | $190K | |
| Sandra Calvin - Officer | Open-market sale | Common Stock | 15,000 | $17.22 | $258K | |
| Sandra Calvin - Officer | Option exercise | Employee stock option (right to buy) | 15,000 | $0.00 | - | |
| Sandra Calvin - Officer | Option exercise | Common Stock | 15,000 | $12.67 | $190K | |
| Sandra Calvin - Officer | Open-market sale | Common Stock | 12,090 | $18.30 | $221K | |
| Sandra Calvin - Officer | Option exercise | Employee stock option (right to buy) | 15,000 | $0.00 | - | |
| Gary A. Lyons | Option exercise | Common Stock | 40,000 | $10.48 | $419K | |
| Gary A. Lyons | Open-market sale | Common Stock | 21,179 | $14.35 | $304K | |
| Gary A. Lyons | Open-market sale | Common Stock | 18,821 | $15.15 | $285K | |
| Gary A. Lyons | Option exercise | Stock option (right to buy) | 40,000 | $0.00 | - |
This is as far as the anonymous view goes. Create a free account for all 69 TVTX filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| GARY LYONS | Director | 5,000 | $318K | View on EDGAR | |
| GARY A LYONS | Director | 5,000 | $311K | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Travere Therapeutics, Inc. (TVTX) had 4 insider filings in the last 90 days, with the most recent on 2026-08-19. The full record for TVTX runs to 69 Form 4 filings, the earliest from 2024-10-04. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of TVTX were filed in the last 90 days.
7 insider sales of TVTX were filed in the last 90 days, totaling $1.36M.
This page tracks TVTX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add TVTX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
